Keyphrases
Acute Lymphoblastic Leukemia
100%
Acute Myeloid Leukemia
15%
Ara-C
9%
B Cells
7%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
7%
Bone Marrow
5%
Cell Lymphoma
5%
Chemotherapy
9%
Childhood Acute Lymphoblastic Leukemia
51%
Childhood Leukemia
8%
Children's Oncology Group
16%
Clinical Trials
5%
Clinical Utility
5%
Combination Chemotherapy
7%
Complete Remission
17%
Cranial Irradiation
5%
Cytosine Arabinoside
7%
Egypt
5%
Etoposide
8%
Event-free Survival
11%
Flow Cytometry
5%
Group Studies
17%
High Risk
18%
High-dose Methotrexate (HD-MTX)
8%
Human Papillomavirus Vaccine
6%
IKZF1
8%
Immunogenicity
5%
Improved Outcomes
8%
L-asparaginase
14%
Leukemia
11%
Leukemia Patients
7%
Marrow
9%
Methotrexate
19%
Minimal Residual Disease
25%
Overall Survival
5%
Pediatric
9%
Pediatric Acute Lymphoblastic Leukemia
5%
Pediatric Oncology
14%
Precursor B-cell Acute Lymphoblastic Leukemia
10%
Prednisone
10%
Prognostic Factors
6%
Relapse Risk
9%
Remission
11%
Remission Induction
9%
Risk Factors
8%
Secondary Acute Myeloid Leukemia (sAML)
5%
Standard Risk
6%
Survival Rate
5%
T Cells
5%
Texas
5%
Tolfenamic Acid
9%
Total Therapy
6%
Type 2 Diabetes Mellitus (T2DM)
7%
United States
6%
VP16
6%
Working Diagnosis
8%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Leukemia
5%
Acute Lymphoblastic Leukemia
67%
Acute Myeloid Leukemia
11%
Asparaginase
6%
Chemotherapy
16%
Childhood Cancer
12%
Clinical Trial
9%
Cytarabine
15%
Disease
10%
Etoposide
7%
Event Free Survival
7%
Immunogenicity
5%
Infection
6%
Intrathecal
8%
Leukemia
15%
Lymphatic Leukemia
6%
Malignant Neoplasm
13%
Methotrexate
28%
Minimal Residual Disease
12%
Non Insulin Dependent Diabetes Mellitus
6%
Prednisone
8%
Remission
26%
Teniposide
6%
Tolfenamic Acid
11%
Vincristine
11%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
83%
Acute Myeloid Leukemia
12%
Adolescence
6%
Chemotherapy
8%
Childhood Cancer
12%
Cytarabine
11%
Disease
9%
Drug Megadose
5%
Etoposide
6%
Event Free Survival
8%
Infection
5%
Leukemia
13%
Leukemia in Children
5%
Leukocyte
8%
Lymphoid Leukemia
5%
Malignant Neoplasm
8%
Maturity Onset Diabetes of the Young
5%
Methotrexate
18%
Minimal Residual Disease
23%
Neoplasm
5%
Oncology
14%
Pediatrics
17%
Precursor
7%
Prevalence
5%
Prognostic Factor
5%
Spontaneous Remission
7%
Treatment Response
5%